Clinical Trials Browser

Phase 1/2 × Burkitt Lymphoma × fludarabine × Clear all

NCT05442515 2026-03-12

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04029038 2023-08-21

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual, Disease Progression

NCT03467256 2023-02-24

CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

Phase 1/2 Unknown

18 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01163201 2017-12-02

T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies

Phase 1/2 Withdrawn

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Lymphoma, Follicular, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03263208 2017-10-20

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

Phase 1/2 Unknown

20 enrolled

Lymphoid

Burkitt Lymphoma